关于2023年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要 求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等有关规定以及《深圳证券交易所 创业板上市公司自律监管指南第 2 号—公告格式》格式指引的相关规定，广东泰 恩康医药股份有限公司（以下简称"公司"）就 2023 年半年度募集资金存放与使 用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 2022 年 1 月 25 日，公司收到中国证券监督管理委员会下发的《关于同意广 东泰恩康医药股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕 203 号），核准公司首次公开发行人民币普通股（A 股）股票 5,910.00 万股，每 股面值 1 元，每股发行价格为 19.93 元，募集资金总额 117,786.30 万元，扣除相 关发行费用（不含税）12,578.23 万元，实际募集资金净额为人民 ...

证券代码：301263 证券简称：泰恩康 编号：投-006 | --- | --- | --- | |----------------|-------------------|--------------| | | □特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □媒体采访 | □ 业绩说明会 | | 类别 | □新闻发布会 | □ 路演活动 | | | □现场参观 | | | | √其他（电话会议） | | 百年保险资产管理有限责任公司、宝盈基金管理有限公司、 贝投资、昶元、创金合信基金管理有限公司、大成基金、丹羿、 德邦证券、东方阿尔法、东方红、东吴基金、东吴证券、方正证 券、沣京资本、峰境基金、光大保德信基金管理有限公司、广东 正圆私募基金管理有限公司、广发基金、国都资管、国融基金管 理有限公司、国盛医药、国盛证券、国寿安保、海通医药、和谐 汇一、恒越基金管理有限公司、华安基金、华创证券、华尚投资、 华泰证券、华西证券、华西证券研究所、华夏基金、华夏久盈、 华鑫证券、汇添富基金管理股份有限公司、惠升基金、惠正投资、 参与单位名称及 嘉合、建投基金、建信基金管理有限责任公司、健顺投资、开源 ...

证券代码： 301263 证券简称：泰恩康 广东泰恩康医药股份有限公司投资者关系活动记录表 编号：投-005 | --- | --- | |----------------|---------------------------| | | □ 分析师会议 | | 投资者关系活动 | □ 业绩说明会 | | 类别 | □ 路演活动 | | | | | | | | | | | | | | | | | | | | 参与单位名称及 | | | 人员姓名 | | | | | | | | | | | | 时间 | （星期五）下午15:00~18:00 | | 地点 | | | 上市公司接待人 | | | 员姓名 | | 本次会议上，公司董事、副总经理兼董事会秘书李挺先生对 公司概况、经营情况及未来发展做了简单介绍，投资者对公司进 行了充分的交流与沟通，随后由各投资者提问，主要交流内容如 投资者关系活动 下： 主要内容介绍 1、2023 年和胃整肠丸的产能情况 答：目前和胃整肠丸市场仍处于缺货状态，自去年四季度以 来生产厂家供货情况已明显改善，2023 年一季度产能相比去年同 期有较大幅度的增长。后续随着厂家机器设备的改造 ...

证券代码： 301263 证券简称：泰恩康 广东泰恩康医药股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |----------------|--------------------------------------|------------------------------------------------------|--------------------------| | | | | 编号：投-004 | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 √ | 业绩说明会 | | | 类别 | □新闻发布会 □ | 路演活动 | | | | □现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名称及 | | | | | 人员姓名 | 线上参与公司泰恩康 | 2022 年度网上业绩说明会的投资者 | | | 时间 | 2023 年 05 月 16 | 日（星期二）下午 15:00-16:00 | | | 地点 | "泰恩康投资者关系"微信小程序 | | | | 上市公司接待人 | 董 ...

证券代码：301263 证券简称：泰恩康 公告编号：2023-035 广东泰恩康医药股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）已于2023年04月27日在 巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年05 月16日（星期二）15:00至16:00时在"泰恩康投资者关系"小程序举行2022年度 网上业绩说明会。本次网上业绩说明会将采用网络远程的方式举行，投资者可登 陆"泰恩康投资者关系"小程序参与互动交流。为广泛听取投资者的意见和建议， 提前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"泰恩康投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"泰恩康投资者关系"小程序，即可参与交 流。 出席本次网上业绩说明会的人员有：公司董事长、总经理郑汉 ...

证券代码： 301263 证券简称：泰恩康 广东泰恩康医药股份有限公司投资者关系活动记录表 编号：投-003 | --- | --- | --- | |----------------|----------------------------|--------------| | | □特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □媒体采访 | □ 业绩说明会 | | 类别 | □新闻发布会 | □ 路演活动 | | | □现场参观 | | | | √ 其他（电话会议） | | | | 方正证券研究所章钟涛 | 唐爱金 | | | 兴证全球基金管理有限公司 | 谢长雁 | | | 宝盈基金管理有限公司 | 吕姝仪 | | | 华夏基金管理有限公司 | 李平祝 | | | 中海基金梁静静 | | | | 天弘基金管理有限公司 | 郭相博 | | | 景顺长城李南西 | | | | 睿远基金吴蔽野 | | | | 中加基金管理有限公司 | 温燕 | | | 中融基金周桓 | | | | 东方红马庆华 | | | 参与单位名称及 | 金信基金谭智汨 | | | 人员姓名 | 中信资管倪秉泽 | | ...

Financial Performance - The company's operating revenue for 2022 was ¥783,480,165.06, representing a 19.86% increase compared to ¥653,651,415.43 in 2021[5]. - Net profit attributable to shareholders for 2022 was ¥174,614,590.33, a 45.43% increase from ¥120,065,941.64 in 2021[5]. - The net cash flow from operating activities was ¥148,814,836.05, up 23.99% from ¥120,023,212.46 in the previous year[5]. - The basic and diluted earnings per share for 2022 were both ¥0.79, reflecting a 16.18% increase from ¥0.68 in 2021[5]. - Total assets at the end of 2022 reached ¥2,038,804,786.88, a significant increase of 116.54% from ¥941,522,180.98 at the end of 2021[5]. - The company's total revenue for 2022 reached ¥783,480,165.06, representing a year-on-year increase of 19.86% compared to ¥653,651,415.43 in 2021[84]. - The pharmaceutical manufacturing segment saw a significant revenue increase of 30.49%, totaling ¥360,854,604.49, while the pharmaceutical agency segment grew by 7.20% to ¥387,745,096.48[84]. - The gross profit margin for the pharmaceutical manufacturing segment improved to 61.04%, an increase of 8.08% from the previous year[87]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[178]. Product Development and R&D - The company is focused on expanding its product offerings and enhancing its R&D capabilities to mitigate market risks[4]. - The company has developed multiple innovative drug projects, including polymer micelles for injection formulations, indicating a strong focus on R&D in chronic disease management[30]. - The company has 34 ongoing self-developed pharmaceutical projects, with 6 having submitted drug registration applications, indicating a strong pipeline for future product approvals[31]. - The company aims to enhance collaboration with research institutions and innovative companies to expand its product offerings and leverage its retail channel advantages[31]. - The company is actively expanding its product pipeline, with 34 major self-developed pharmaceutical projects, 6 of which have submitted drug registration applications[72]. - The company plans to continue increasing R&D investments, with expectations of launching more than two self-developed drugs annually over the next three years[82]. - Research and development investment amounted to ¥54,037,400, marking a 49.76% increase year-on-year, with 34 major self-developed pharmaceutical projects currently in progress[82]. - The company is committed to research and development of new products and technologies to maintain competitive advantage[170]. - The company is investing in research and development for new products aimed at improving healthcare solutions[145]. Market Trends and Opportunities - The two-sex health medication market is rapidly growing, driven by changing societal attitudes and increasing health demands, with significant potential for PE and ED treatment drugs[35]. - The ophthalmic medication market in China saw sales exceeding 12 billion CNY in 2021, with a year-on-year growth of 15.01%, indicating a robust demand for eye care products[36]. - The gastrointestinal medication market in China was approximately 30 billion CNY in retail sales in 2021, with a compound annual growth rate of 5.75% from 2018 to 2021[39]. - The Chinese traditional medicine market is projected to exceed 110 billion CNY in sales in 2022, supported by government initiatives to promote traditional medicine[40]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[178]. Governance and Compliance - The company has a comprehensive governance structure with all board members present for the report's approval[4]. - The company maintains independent operations from its controlling shareholders and actual controllers, ensuring no interference in management[153]. - A transparent performance evaluation and incentive mechanism for senior management has been established, linking compensation to company performance[155]. - The company has established a complete corporate governance structure in compliance with the Company Law and Securities Law, ensuring independent operation of its functional departments[163]. - The company has a dedicated financial department and an independent financial accounting system, allowing for independent financial decision-making[162]. Risks and Challenges - The company acknowledges potential risks including R&D risks, drug market entry risks, and registration renewal risks for imported drugs[4]. - The company faces risks related to R&D failures, which could impact the recovery of investments and overall profitability[139]. - There is a risk that newly developed drugs may not meet market demands or face competition from similar products, affecting the company's revenue[140]. - The stability of the company's agency operations is crucial for its revenue, with potential risks if agreements with suppliers are not maintained[141]. - The company must ensure timely re-registration of imported drug certificates to avoid disruptions in production and operations[143]. Strategic Initiatives - The company plans to distribute a cash dividend of 7.00 RMB per 10 shares (including tax) to all shareholders, based on a total of 236,387,500 shares[4]. - The company has established three major pharmaceutical R&D technology platforms, including functional excipients and nanomedicine[53]. - The company aims to strengthen its R&D capabilities, focusing on innovative drug research and development, with an emphasis on functional excipients and nanomedicine technologies[135]. - The company plans to enhance its digital platforms to better serve its customer base and improve operational efficiency[145]. - The company is actively seeking partnerships with other firms to leverage synergies in product development and market expansion[145]. Employee and Management Structure - The total number of employees at the end of the reporting period was 1,002, with 386 in the parent company and 616 in major subsidiaries[196]. - The company has established a comprehensive salary management system and implements a performance appraisal system to enhance employee satisfaction and align with corporate goals[198]. - Employee training programs are conducted across multiple levels and formats, focusing on new employee orientation, on-the-job training, and management skills enhancement[199]. - The company has a structured approach to employee training, aiming to improve overall employee quality and innovation capabilities[199]. - The company has seen a shift in its management structure to better align with its strategic goals and market demands[169].

Financial Performance - The company's revenue for Q1 2023 was CNY 193,788,912.58, representing a 5.73% increase compared to CNY 183,290,412.29 in the same period last year[5]. - Net profit attributable to shareholders decreased by 3.51% to CNY 51,985,920.77 from CNY 53,875,611.94 year-on-year[5]. - The net profit after deducting non-recurring gains and losses fell by 11.88% to CNY 46,808,747.53 compared to CNY 53,120,767.73 in the previous year[5]. - The total operating revenue for Q1 2023 was CNY 193,788,912.58, an increase of 5.6% compared to CNY 183,290,412.29 in Q1 2022[25]. - The net profit for Q1 2023 was CNY 51,674,794.42, a decrease of 4.1% from CNY 53,874,484.71 in Q1 2022[26]. - The total comprehensive income attributable to the parent company is CNY 51,876,683.00, down from CNY 54,106,652.71, reflecting a decline of approximately 4.3%[27]. - Basic and diluted earnings per share for Q1 2023 are both CNY 0.22, compared to CNY 0.30 in the previous period, indicating a decrease of 26.7%[27]. Assets and Liabilities - The company's total assets increased by 7.04% to CNY 2,182,265,103.71 from CNY 2,038,804,786.88 at the end of the previous year[5]. - The total liabilities as of March 31, 2023, were CNY 250,024,516.91, compared to CNY 184,843,822.55 at the start of the year[23]. - The company's cash and cash equivalents decreased to CNY 553,119,978.27 from CNY 806,786,386.60 at the beginning of the year[21]. - The company's inventory increased to CNY 93,157,668.83 from CNY 80,523,332.56 at the beginning of the year, indicating a potential increase in production or sales[22]. Cash Flow - Cash flow from operating activities decreased by 2.27% to CNY 43,734,808.96 compared to CNY 44,750,344.20 in the previous year[5]. - Cash inflow from operating activities totals CNY 187,555,195.15, an increase from CNY 167,719,799.27, representing a growth of 11.0%[30]. - The net cash flow from operating activities is CNY 43,734,808.96, slightly down from CNY 44,750,344.20, a decrease of 2.3%[30]. - Cash outflow from investing activities is CNY 723,535,880.95, significantly higher than CNY 12,493,985.79 in the previous period, indicating increased investment activity[30]. - The net cash flow from investing activities is -CNY 296,882,888.97, compared to -CNY 12,493,485.79, reflecting a larger cash outflow[30]. - The net cash flow from financing activities is -CNY 516,082.76, a decrease from CNY 1,060,775,223.32 in the previous period, indicating reduced financing activity[31]. - The ending cash and cash equivalents balance is CNY 553,069,978.27, down from CNY 1,229,499,447.67, a decline of 55.0%[31]. Research and Development - Research and development expenses surged by 141.08% to CNY 15,898,325.39 from CNY 6,594,626.38 in the same period last year, indicating increased investment in R&D[12]. - Research and development expenses for Q1 2023 were CNY 15,898,325.39, significantly higher than CNY 6,594,626.38 in Q1 2022, reflecting a focus on innovation[26]. - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[18]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,519[14]. - Major shareholder Zheng Hanjie holds 20.77% of shares, totaling 49,098,900 shares[14]. - Major shareholder Sun Weiwen holds 15.56% of shares, totaling 36,787,150 shares[14]. - The total number of restricted shares at the beginning of the period was 182,722,522, with 73,558,710 shares released during the period[17]. - The company has a total of 109,163,812 restricted shares remaining at the end of the period[17]. - The top ten shareholders hold a significant portion of the company's equity, with the largest shareholder holding over 20%[14]. - The company has established relationships among major shareholders, indicating potential coordinated actions[15]. Acquisitions and Market Expansion - The company plans to acquire 50% equity of Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd[18]. - The company completed the acquisition of a 50% stake in Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd. for CNY 200 million, enhancing its product pipeline[19]. - The company is exploring market expansion opportunities through acquisitions and partnerships[18]. Goodwill - The company reported a significant increase in goodwill by 634.24% to CNY 200,643,602.10 due to acquisitions made during the reporting period[9]. - The company reported a significant increase in goodwill to CNY 200,643,602.10 from CNY 27,326,563.93, indicating potential acquisitions or investments[22].

Financial Performance - Revenue for Q3 2022 reached ¥198,658,228.89, an increase of 30.92% year-over-year[7] - Net profit attributable to shareholders was ¥49,601,390.11, up 123.79% compared to the same period last year[7] - Net profit excluding non-recurring gains and losses was ¥45,622,308.85, reflecting a growth of 111.19% year-over-year[7] - Basic earnings per share for Q3 2022 was ¥0.21, up 61.54% from the same period last year[7] - For the first three quarters of 2022, the company reported total revenue of CNY 573.43 million, up 22.47% year-on-year[29] - The net profit attributable to shareholders for the first three quarters was CNY 127.16 million, an increase of 60.21% compared to the previous year[29] - The company reported a total comprehensive income of ¥127,739,140.77, up from ¥79,453,880.62, marking an increase of 60.8%[52] Assets and Equity - Total assets at the end of the reporting period amounted to ¥1,985,620,844.01, representing a 110.89% increase from the previous year[7] - Shareholders' equity reached ¥1,807,036,365.30, a significant rise of 154.53% compared to the end of the previous year[7] - The total assets of the company reached CNY 1.99 billion as of September 30, 2022, compared to CNY 941.52 million at the start of the year[40] - Total equity attributable to shareholders of the parent company increased significantly to ¥1,807,036,365.30 from ¥709,958,986.51, representing a growth of 154.5%[46] Cash Flow - Cash flow from operating activities for the year-to-date was ¥97,054,451.32, an increase of 70.49% year-over-year[7] - Net cash flow from operating activities rose by 70.49% to ¥97,054,451.32, primarily driven by increased cash receipts from sales[16] - Operating cash inflow totaled $571,083,668.76, an increase from $450,506,088.42 in the previous period, reflecting a growth of approximately 27%[57] - The net cash flow from financing activities was $893,059,310.56, contrasting with a net outflow of -$28,849,751.10 in the previous period, highlighting improved financial stability[60] - The company reported a net increase in cash and cash equivalents of $288,199,555.88, compared to a decrease of -$11,424,367.63 previously, indicating a positive cash position[60] Investments and Expenses - The company reported a 426.32% increase in contract assets, totaling ¥15,996,718.49, due to progress in R&D projects[12] - Management expenses increased by 30.03% to ¥41,727,809.43 due to higher employee compensation and listing-related costs[16] - Financial expenses decreased by 66.07% to ¥1,163,180.07 as a result of reduced bank loan interest after repayment[16] - Investment income surged by 2016.84% to ¥1,969,614.16 due to increased returns from financial products purchased with idle funds[16] - Research and development expenses rose to ¥25,220,770.88, an increase of 13.5% compared to ¥22,318,014.11 in the previous year[47] Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,418[20] - Major shareholder Zheng Hanjie holds 20.77% of shares, totaling 49,098,900 shares[20] Tax and Liabilities - The company reported a 76.34% increase in income tax expenses to ¥23,848,515.01 due to profit growth[16] - Total liabilities decreased to ¥178,728,524.91 from ¥231,714,080.57, reflecting a reduction of approximately 22.9%[46] Product Performance - The core product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) generated sales of CNY 163.84 million, a 65.87% increase year-on-year[32] - The "He Wei Zheng Chang Wan" (Stomach and Intestine Pills) achieved sales of CNY 100.87 million, growing by 26.75% year-on-year[32] - The company is facing supply chain challenges for its core product "He Wei Zheng Chang Wan" due to domestic pandemic fluctuations and logistics issues[32]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[21]. - The net profit attributable to shareholders was RMB 80 million, up 20% compared to the same period last year[21]. - The company's operating revenue for the reporting period was ¥374,774,136.13, representing an increase of 18.42% compared to the same period last year[30]. - The net profit attributable to shareholders was ¥77,557,085.13, reflecting a growth of 35.58% year-over-year[30]. - The net profit after deducting non-recurring gains and losses was ¥73,995,209.37, which is an increase of 58.43% compared to the previous year[30]. - The basic earnings per share increased to ¥0.37, up 15.63% from ¥0.32 in the same period last year[33]. - The core product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) generated sales revenue of 105.51 million yuan, a significant increase of 42.66% compared to the same period last year[77]. - The sales revenue of "He Wei Zheng Chang Wan" (Stomach and Intestine Pills) increased by 23.52% year-on-year, reaching 61.85 million yuan[77]. Research and Development - The company plans to invest RMB 100 million in R&D for new drug development in the next fiscal year[21]. - The company has established three major pharmaceutical R&D technology platforms to support its development efforts[44]. - The company’s R&D investment reached 20.26 million yuan, representing a year-on-year growth of 16.35%[79]. - The company plans to continue increasing R&D investment, anticipating that more than 2 self-developed drugs will receive registration approval annually over the next three years[79]. - The company focuses on enhancing its new drug research capabilities, leveraging functional excipients, nanomedicine technology platforms, and biosimilar drug development to strengthen its competitive edge and market expansion[132]. Market Expansion - User data indicates a 25% increase in the number of active customers, reaching 1 million by the end of June 2022[21]. - The company has expanded its market presence by entering three new provinces, increasing its distribution network by 30%[21]. - The company aims to launch two new products by the end of 2022, targeting a market share increase of 10% in the respective segments[21]. - The company’s marketing network covers 28 provincial regions in China, supported by over 300 professional sales personnel[78]. - The company has established long-term partnerships with major pharmaceutical distribution companies, enhancing its market reach and sales capabilities[78]. Product Development - The company's self-developed product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) accounted for 45.55% of total revenue in the first half of 2022[44]. - The newly approved "Aiting Wei" (Tadalafil Tablets) was launched in August 2022, expected to leverage existing marketing channels for rapid market penetration[79]. - The company’s main products include "Aiting Jiu" Dapoxetine Hydrochloride Tablets and "Aiting Wei" Tadalafil Tablets, both classified as prescription drugs for male sexual health[52]. - The company’s ophthalmic product "Woliting" is specifically designed for various retinal diseases, indicating a focus on specialized treatments[50]. Financial Management - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥304,843,771.43, a rise of 2,882.66% compared to ¥10,220,524.28 in the previous year, mainly due to funds raised from the initial public offering[93]. - The company's total assets included cash and cash equivalents of ¥442,473,163.91, representing 22.86% of total assets, a 221.50% increase from the previous year[98]. - The company’s financial expenses decreased by 73.09% to ¥512,413.13, down from ¥1,903,853.87 in the previous year, due to reduced interest expenses after repaying bank loans[93]. - The company raised a total of ¥117,786.30 million from its initial public offering, with a net amount of ¥105,208.07 million after deducting issuance costs[12]. Environmental Compliance - The company has focused on environmental protection and compliance, with all subsidiaries achieving standard emissions during the reporting period[157]. - The company’s subsidiary, Tai En Kang Pharmaceutical Factory, has implemented measures to ensure that emissions meet standards, including VOCs treatment and wastewater management[158]. - The wastewater from Tai En Kang Pharmaceutical Factory meets the second-stage tertiary standard limits for water pollutants[158]. - The company has taken measures to reduce noise pollution from production equipment, ensuring compliance with industrial noise emission standards[160]. Related Party Transactions - The company reported a total of 210.77 million yuan in related party transactions during the reporting period, with 98.70% attributed to product sales[182]. - The company confirmed that all related party transactions were conducted at market prices and did not deviate from market rates[182]. - The approved transaction limit for related party transactions was 1,470 million yuan, and the actual transactions did not exceed this limit[182].